Botanix Pharmaceuticals (ASX:BOT) reported Wednesday a fiscal first-half loss of AU$0.017 per diluted share, wider compared with a loss of AU$0.0038 a year earlier.
Revenue for the six months ended Dec. 31, 2024, was AU$345.7 million, compared with AU$377.9 million a year earlier.
The company's shares fell 1% in recent Thursday trade.